Document is current
Any future updates will be listed below
-
Authors
Hu, Tingyang
Liu, Qiang
Dai, Qile
Buchman, Aron S.
Bennett, David A.
Tasaki, Shinya
Wang, Yanling
Seyfried, Nicholas T.
De Jager, Philip L.
Epstein, Michael P.
Yang, Jingjing
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (R35GM138313, R35GM138313, R35GM138313, R35GM138313)
National Institute on Aging (AG071170, AG071170)
National Institutes of Health (P30AG10161, P30AG10161, P30AG10161, P30AG10161, P30AG10161, P30AG10161)
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 25 May 2025
First Online: 18 June 2025
Declarations
:
: Summary-level pQTL data of brain, CSF, and plasma, and summary GWAS data of AD dementia were used for conducting PWAS in this study. These data are de-identified and publicly available, requiring no ethics approval. All de-identified omics data are not considered as human data per NIH guidelines. All ROSMAP participants enrolled without known dementia and agreed to detailed clinical evaluation and brain donation at death []. Both studies were approved by an Institutional Review Board of Rush University Medical Center (ROS IRB# L91020181, MAP IRB# L86121802). Both studies were conducted according to the principles expressed in the Declaration of Helsinki. Each participant signed an informed consent, Anatomic Gift Act, and an RADC Repository consent (IRB# L99032481) allowing her data and biospecimens to be repurposed. ROS/MAP transcriptomic and whole genome sequencing data used for TWAS in this study were shared with a data use agreement.
: Not applicable.
: The authors declare no competing interests.
